May 2022 Top Biopharma Deal: Dragonfly Therapeutics – Gilead Sciences NK cell engager for cancer/inflammation
May 2022 Top Biopharma Deal Upfront
Dragonfly Therapeutics development and commercialization deal with Gilead Sciences for solid tumors
Highlighted Deal Financial Comps
Date Announced:
May 2, 2022
Total Deal Value:
$300M + Undisclosed opt-ins and milestones
Upfront Cash:
$300M
Upfront Equity:
n/a
Option Payments:
Undisclosed opt-in payments
Total Milestones:
Undisclosed dev., reg., and sales milestones
Royalties:
Up to 20% royalties on worldwide net sales
Cost & Profit Split:
n/a
Deal Synopsis
The Asset:
Dragonfly Therapeutics’ DF-7001 5T4-targeting NK cell engager-based immunotherapy for solid tumors
Deal Structure:
Development and Commercial License
Partnership Features:
Collaborative Development, No Shared Cost; Option to Add NK Cell Engager Programs from the Tri-specific NK Engager (TriNKET) Platform
Deal Details:
- Dragonfly granted Gilead exclusive, worldwide rights to develop and commercialize Dragonfly’s 5T4-targeting immunotherapy DF-7001 for the treatment of cancer and inflammation.
- Gilead has an exclusive, worldwide option to develop and commercialize additional NK cell engager programs by using its Tri-specific NK Engager (TriNKET) platform after the completion of certain preclinical activities.
- Dragonfly will receive $300M up front and is eligible to receive undisclosed opt-in payments and development, regulatory, and commercial milestones, plus up to 20% royalties.
Last Month:
Congrats to Dragonfly Therapeutics and Gilead Sciences for landing DealForma’s May 2022 Top Biopharma Deal. Last month’s Deal of the Month was Harbour BioMed and AstraZeneca’s bispecific antibody deal for cancer treatment. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
20,378
Licensing Deals
17,730
Funding Rounds
4,034
M&A
31,012
Company Profiles
5,478
Other Deals
26,505
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...